

## Novavax COVID-19 vaccine, adjuvanted – Expanded emergency use authorization

- On August 19, 2022, the <u>FDA announced</u> the emergency use authorization (EUA) of the <u>Novavax</u> <u>COVID-19 vaccine</u>, <u>adjuvanted</u>, for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older.
  - The Novavax COVID-19 vaccine, adjuvanted was previously authorized under an EUA for adults 18 years of age and older.
- The Novavax COVID-19 vaccine, adjuvanted contains purified SARS-CoV-2 spike protein and Matrix-M adjuvant. Adjuvants are incorporated into some vaccines to enhance the immune response of the vaccinated individual.
- The efficacy of Novavax COVID-19 vaccine, adjuvanted was established in a randomized, observer-blinded, placebo-controlled study in 2,247 participants who were 12 to 17 years of age and did not have evidence of SARS-CoV-2 infection. Participants received two doses of the Novavax COVID-19 vaccine, adjuvanted (0.5 mL) or placebo three weeks apart.
  - Noninferior immune responses as assessed by geometric mean titers and seroconversion rates were demonstrated in a comparison of adolescents 12 through 17 years of age to participants 18 through 25 years of age.
  - Vaccine efficacy was 78.29% (95% CI: 37.55, 92.45) with 5 cases of mild COVID-19 reported in the Novavax COVID-19 vaccine group vs. 11 cases in the placebo group.
  - The delta variant was the predominant variant while the study was conducted.
- The most common adverse reactions with Novavax COVID-19 vaccine, adjuvanted use in individuals 12 to 17 years of age were injection site pain/tenderness, headache, fatigue/malaise, muscle pain, nausea/vomiting, joint pain, fever, injection site swelling, and injection site redness.
- The recommended dose of Novavax COVID-19 vaccine, adjuvanted in individuals 12 years of age and older is given intramuscularly as a primary series of two doses (0.5 mL each) 3 weeks apart.
- The <u>Centers for Disease Control and Prevention's Director has already recommended</u> the Novavax COVID-19 vaccine, adjuvanted be used in individuals 12 to 17 years of age. No public meetings are planned for this expanded use



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews<sup>®</sup> is published by the Optum Rx Clinical Services Department.